Ketamine Therapy for PTSD.

Intravenous (IV) ketamine therapy delivers ketamine through a medically supervised infusion. Ketamine acts primarily on NMDA receptors involved in glutamate signaling, learning, and neuroplasticity. Researchers have investigated whether these effects can reduce symptoms of post-traumatic stress disorder.

IV ketamine is not FDA-approved specifically for PTSD. Its use for PTSD is off-label and requires an individualized medical evaluation.

Small randomized clinical trials have reported short-term reductions in PTSD symptom severity after IV ketamine infusions. However, some patients do not experience meaningful improvement, and larger studies are needed to establish long-term effectiveness and safety.

Ketamine is not a guaranteed treatment for PTSD and does not replace established trauma-focused psychotherapy.

PTSD can involve intrusive memories, nightmares, avoidance, emotional distress, hypervigilance, sleep problems, and changes in mood. Clinical research has primarily evaluated changes in overall PTSD symptom severity rather than proving reliable improvement in every individual symptom.

Your medical provider can discuss realistic expectations based on your symptoms and treatment history.

Experiences vary. Ketamine can temporarily alter perception, thoughts, and emotional awareness. Some patients may reflect on difficult experiences, while others may not think about their trauma at all. Distressing memories or anxiety can also occur.

You are not required to recount traumatic events during an infusion. Discuss known triggers, dissociation, and previous treatment experiences with your clinical team beforehand.

Tell your medical provider if you experience depersonalization, derealization, dissociative episodes, or significant distress related to altered states of awareness. Ketamine itself can cause temporary dissociative effects.

Your team should evaluate whether treatment is appropriate and discuss monitoring and support. Some patients may need additional precautions or a different treatment approach.

Nightmares and disrupted sleep are common PTSD symptoms. Some patients report changes in sleep alongside improvements in overall mental health, but ketamine has not been established as a reliable standalone treatment for PTSD-related nightmares.

Evidence-based approaches for sleep problems and nightmares should also be discussed with your treating clinician.

Veterans, active-duty service members, and first responders may be considered for IV ketamine therapy following an appropriate medical evaluation. Research has included military and veteran populations, although findings do not establish ketamine as a first-line PTSD treatment.

PTSD related to combat, occupational trauma, or other experiences should be evaluated individually. Coordination with existing clinicians may be appropriate.

Many patients continue working with their existing mental health providers during medical treatment. Eye movement desensitization and reprocessing (EMDR), cognitive processing therapy, and prolonged exposure therapy are established PTSD treatment approaches.

Discuss the timing of psychotherapy sessions around ketamine infusions with your clinicians. Research has not established that ketamine reliably makes trauma processing easier or more effective.

Ketamine-assisted psychotherapy (KAP) combines ketamine treatment with psychotherapy or structured therapeutic support. Integration sessions may focus on reflecting on the experience and connecting it to broader treatment goals.

KAP is still being studied for PTSD, and there is no established guarantee that it produces more durable outcomes. Ask our team about available integration options and the role of your existing therapist.

No. Trauma-focused psychotherapies are evidence-based treatments for PTSD, and certain medications can also be helpful. IV ketamine may be considered as an off-label option in selected cases, but it should not automatically replace established care.

Do not stop therapy or change prescribed medications without discussing the plan with your treating clinicians.

Clinical studies have evaluated both single infusions and repeated courses. Northwest Ketamine Clinics' standard mental health Healing Pathways are structured around six IV ketamine sessions, subject to medical evaluation.

There is no universally established FDA-approved ketamine dosing schedule for PTSD. The appropriate treatment plan depends on clinical eligibility and individual response.

Some small randomized studies have reported improvement in PTSD symptom scores within approximately 24 hours of treatment. However, research findings do not mean that every patient will improve that quickly or respond at all.

We cannot promise a particular response or timeline for an individual patient.

Duration varies. In one small repeated-infusion clinical trial, some participants experienced improvement extending beyond the treatment series, but symptoms later returned for some responders.

Long-term outcomes, ideal treatment frequency, and the role of maintenance infusions remain uncertain. No particular duration of relief can be guaranteed.

Maintenance infusions may be discussed when a patient has experienced a meaningful initial response. However, there is no universally established ketamine maintenance schedule for PTSD.

Decisions about additional treatment should consider symptom changes, tolerability, risks, and the overall mental health treatment plan.

Patients may experience changes in perception, a sense of detachment, altered awareness, dizziness, or sedation. Some experiences feel neutral or calming, while others can be uncomfortable or anxiety-provoking.

Our clinical team reviews what to expect before treatment and monitors patients during infusions. People with a trauma history should discuss triggers and concerns in advance.

Ketamine requires medical supervision. Potential side effects include elevated blood pressure, nausea, dizziness, sedation, anxiety, and temporary dissociation. Repeated treatment can introduce other risks that clinicians must consider.

Your provider reviews medical history, psychiatric symptoms, and medication use before deciding whether an infusion is appropriate.

Some cardiovascular conditions, uncontrolled blood pressure, active psychotic symptoms, certain substance-use concerns, pregnancy, and other health factors may make treatment inappropriate or require further evaluation.

A PTSD diagnosis alone does not establish eligibility. The medical provider determines candidacy after reviewing the individual's clinical circumstances.

No. Spravato (esketamine) is not FDA-approved specifically for PTSD. It is a nasal prescription treatment used for certain depressive conditions under specific prescribing and monitoring requirements.

IV ketamine and Spravato are different treatments. A patient who has both PTSD and depression may need a separate evaluation for each condition and treatment option.

Northwest Ketamine Clinics offers mental health Healing Pathways, with the total cost depending on the selected treatment package and included services. Our intake team can review current pricing before you commit to treatment.

CareCredit financing may be available to qualifying patients. Promotional terms and credit approval requirements apply. IV ketamine for PTSD is typically a cash-pay service, and insurance coverage is limited.

Northwest Ketamine Clinics offers medically supervised IV ketamine therapy through clinics in Seattle, Bellevue, and Tacoma, Washington. Patients considering treatment for PTSD can start with a free introductory call to review their concerns, treatment options, and scheduling.

Following an individualized medical evaluation, the clinical team determines whether treatment is appropriate. Patients must arrange transportation after an infusion and should not drive themselves home.